Login / Signup

Cannabidiol Effect on Cue-Induced Craving for Individuals with Opioid Use Disorder Treated with Buprenorphine: A Small Proof-of-Concept Open-Label Study.

Joji SuzukiBianca MartinSara ProstkoPeter Ray ChaiRoger D Weiss
Published in: Integrative medicine reports (2022)
Given the high risk for bias in a small uncontrolled open label study such as this, results must be interpreted with caution. A larger adequately powered trial with a suitable control group is needed to confirm the finding that CBD may help to reduce cue-induced craving among individuals with OUD currently on buprenorphine treatment. Research should further evaluate whether adjunctive use of CBD can improve clinical outcomes for individuals with OUD maintained on buprenorphine. ClinicalTrials.gov (NCT04192370).
Keyphrases
  • open label
  • clinical trial
  • phase ii
  • phase iii
  • high glucose
  • study protocol
  • diabetic rats
  • squamous cell carcinoma
  • drug induced
  • endothelial cells
  • double blind
  • replacement therapy